Clareo Biosciences and PacBio Team Up to Advance Immunosequencing

Clareo Biosciences is investing in immunosequencing as a tool to better understand the immune system and accelerate biomarker development. Its goal is to create assays that allow for complete profiling of immune receptor repertoires at both the DNA and RNA levels, thus providing a "complete picture" of the immune response in various diseases. To meet this challenge, the company has partnered with Pacific Biosciences (PacBio), renowned for its HiFi long-read platform. This technology is particularly useful for studying the immune system, as it allows for detailed analysis of the variations and diversity of receptors that mediate the body's defenses.

The collaboration between Clareo and PacBio seeks to leverage the power of long-read sequencing along with Clareo's applied expertise to identify immune signatures and design predictive algorithms to aid in patient diagnosis and stratification. This is expected to accelerate biomarker research and open up new opportunities in personalized medicine, providing greater insight into the underlying mechanisms of various diseases.

Harnessing the power of immunogenetics to improve human health - Clareo Bioscienses

Read more

https://www.genomeweb.com/sequencing/clareo-biosciences-banks-pacbio-long-reads-comprehensive-immune-receptor-profiling

https://clareobio.com/